Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice

Okamoto, Masahiro; Tajiri, Wakako; Ueo, Hiroki; Masuda, Takanobu; Ijichi, Hideki; Koga, Chinami; Nakamura, Yoshiaki; Taguchi, Kenichi; Ohno, Shinji; Tokunaga, Eriko

doi:10.21873/anticanres.14314

Cited by 5 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, the OS benefits were similar in both the matched neoadjuvant cases and adjuvant controls who also underwent targeted therapy. A previous study suggested that neoadjuvant chemotherapy is the preferred treatment strategy for patients with TNBC and HER2-enriched breast cancer ( 26 ), and the addition of an anti-HER2 regimen in both adjuvant and neoadjuvant settings can lead to favorable survival outcomes ( 27 – 29 ). However, in the present study, the treatment benefits of chemotherapy in both adjuvant and neoadjuvant settings were not observed in the patients with luminal A breast cancer following matching, which contrasts with the findings of a previous study ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case‑control study

et al. 2022

View full text Add to dashboard Cite

Immediate breast reconstruction after mastectomy combined with chemotherapy is the preferred option for patients with early-stage breast cancer who require both superior clinical and aesthetic outcomes. The present study aimed to determine the survival benefits of neoadjuvant and adjuvant chemotherapy for patients with early-stage breast cancer who have undergone immediate breast reconstruction after mastectomy in Taiwan. The present study compared overall survival (OS) following neoadjuvant or adjuvant chemotherapy in 139 patients with early-stage breast cancer who underwent immediate breast reconstruction after mastectomy. Patient data were used retrospectively as an unmatched cohort. Next, 37 neoadjuvant cases were matched with 37 adjuvant controls through 1:1 age-, clinical stage-, and molecular subtype-matching. OS differences between the cases and controls were determined using Kaplan-Meier survival curve analyses. Here, 77.7 and 81.1% of the unmatched and matched cohort patients were aged <50 years, respectively. Of the matched neoadjuvant cases, 10 (15.6%) reached pathologic complete response after neoadjuvant chemotherapy, whereas 5 (13.5%) neoadjuvant cases succumbed during the study period. The neoadjuvant matched cases demonstrated a significantly poor OS with their adjuvant matched controls (P=0.044); nevertheless, the stratification analysis results demonstrated that the survival differences between the neoadjuvant and the adjuvant controls decreased after matching. Targeted therapy demonstrated the same OS benefits for both the neoadjuvant matched cases and adjuvant matched controls (P=1.000). This study provided matched case-control evidence for the feasibility of neoadjuvant chemotherapy combined with targeted therapy for patients with early-stage breast cancer with immediate breast reconstruction after mastectomy in a Taiwanese female population.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case‑control study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This highlights the importance of further investigation of HER2 in OSCC development. Currently, small molecule inhibitors or antibodies targeting HER2 have been approved for treatment of patients with HER2-positive breast cancer, non-small cell lung cancer (NSCLC), and gastroesophageal cancer (Iqbal and Iqbal, 2014;Cameron et al, 2017;Kneissl et al, 2017;Liu et al, 2018;Okamoto et al, 2020). Two FDA-approved HER2 monoclonal antibodies (mAbs), namely trastuzumab, and pertuzumab, have shown antitumor effects by attacking HER2 signaling (Gerson et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Circulating Natural Autoantibodies to HER2-Derived Peptides Performed Antitumor Effects on Oral Squamous Cell Carcinoma

Liu

He²,

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Natural autoantibodies play a crucial role in destruction of malignant tumors due to immune surveillance function. Epidermal growth factor receptor 2 (HER2) has been found to be highly expressed in a variety of epithelial tumors including oral squamous cell carcinoma (OSCC). The present study was thus undertaken to investigate the effect of anti-HER2 natural autoantibodies on OSCC. Compared with cancer-adjacent tissues, cancer tissues from OSCC patients exhibited higher HER2 expression especially in those with middle & advanced stage OSCC. Plasma anti-HER2 IgG levels examined with an enzyme-linked immunosorbent assay (ELISA) developed in-house showed differences between control subjects, individuals with oral benign tumor and patients with OSCC. In addition, anti-HER2 IgG-abundant plasma was screened from healthy donors to treat OSCC cells and to prepare for anti-HER2 intravenous immunoglobulin (IVIg). Both anti-HER2 IgG-abundant plasma and anti-HER2 IVIg could significantly inhibit proliferation and invasion of OSCC cells by inducing the apoptosis, and also regulate apoptosis-associated factors and epithelial-mesenchymal transition (EMT), respectively. Besides, the complement-dependent cytotoxicity (CDC) pathway was likely to contribute to the anti-HER2 IgG mediated inhibition of OSCC cells. After the HER2 gene was knocked down with HER2-specific siRNAs, the inhibitory effects on OSCC cell proliferation and apoptotic induction faded away. In conclusion, human plasma IgG, or IVIg against HER2 may be a promising agent for anti-OSCC therapy.

show abstract

Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics

O’Shaughnessy¹,

Gradishar²,

O’Regan³

et al. 2023

Clinical Breast Cancer

View full text Add to dashboard Cite

Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice

Cited by 5 publications

References 24 publications

Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case‑control study

Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case‑control study

Circulating Natural Autoantibodies to HER2-Derived Peptides Performed Antitumor Effects on Oral Squamous Cell Carcinoma

Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics

Contact Info

Product

Resources

About